Citations

Showing 10 of 108152 citations.

Pulmonary Hypertension: Controversial and Emerging Topics
Charnin, Jonathan E.

Mayo Clinic

Anesthesia & Analgesia | July 13, 2021 | Volume: 133 | Issue: 2 | Pages: e18-e19

10.1213/ane.0000000000005616 Get It

SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology
Chukwueke, Ugonma , Vera, Elizabeth , Acquaye, Alvina , Hervey‐Jumper, Shawn L. , Odia, Yazmín , Klesse, Laura J. , Dunbar, Erin, Fonkem, Ekokobe , Thomas, Alissa A. , Werbowetski‐Ogilvie, Tamra E. , Camelo‐Piragua, Sandra , Gatson, Na Tosha , Fuente, Macarena I. de la , Porter, Alyx B. , Jackson, Sadhana , Fonkem, Ekokobe , Armstrong, Terri S , Jackson, Sadhana , Gatson, Na Tosha N , De La Fuente, Macarena , Odia, Yazmin , Klesse, Laura J , Sharma, Akanksha , Armstrong, Terri S.

Mayo Clinic

Neuro-Oncology | July 13, 2021 | Volume: 23 | Issue: 11 | Pages: 1845-1858

10.1093/neuonc/noab172 | PMID 34302487 Get It

Abstract Background Neuro-oncology has grown tremendously since 2010, marked by increasing society membership, specialized clinical expertise, and new journals. Yet, modest improvement in racial/ethnic diversity amongst clinical trial participants, researchers, and clinicians led us to conduct a survey to identify opportunities to enhance diversity and inclusiveness amongst neuro-oncology professionals. Methods In summer 2020, the Women and Diversity Committee of the Society for Neuro-Oncology (SNO) distributed an anonymous online survey to members and affiliates including the European Association of Neuro-Oncology (EANO), Asian Society for Neuro-Oncology (ASNO), Society for Neuro-Oncology Latin America (SNOLA) and Society for Neuro-Oncology Sub-Saharan Africa (SNOSSA). The survey captured personal and professional characteristics, biases, effective mentorship qualities, career service metrics, and suggested field/society changes. Results were analyzed by geography, profession, age, racial/ethnic, and sexual identity. Standard descriptive statistics characterized the study population. Results The 386 respondents were predominantly female (58%) with a median age range of 40–49 years (31%), White (65%), and SNO members (97%). Most worked in North America (77%) in a research profession (67%). A majority of White respondents reported never experiencing biases (64%), while the majority of non-White respondents reported unconscious biases/microaggressions, followed by a lack of/limited mentorship. Qualitative assessments showcased that personal/professional success metrics were linked to needed improvements in diversity and inclusion efforts within the neuro-oncology field. Conclusions The prevalence of racial/ethnic biases and poor mentorship rates amongst underrepresented groups in neuro-oncology is high and potentially linked to the limited diverse representation amongst members and affiliates. These findings warrant a swift implementation of equity and inclusion practices within the neuro-oncology field.
Association of Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment Trials
Mo, Julia , Darke, Amy K. , Guthrie, Katherine A. , Sloan, Jeff A. , Unger, Joseph M. , Hershman, Dawn L. , O’Rourke, Mark Allen , Bakitas, Marie , Krouse, Robert S. , O'Rourke, Mark , Hershman, Dawn L , Unger, Joseph M

Mayo Clinic

JCO Oncology Practice | July 13, 2021 | Volume: 17 | Issue: 8 | Pages: e1246-e1257

10.1200/op.20.01096 | PMID 34255538 Get It

PURPOSE: Patient-reported outcomes may be associated with cancer outcomes. We evaluated clinically significant fatigue (CSF), overall survival, adverse events (AEs), and quality of life (QOL) during cancer treatment. METHODS: We compared outcomes in four phase II or III chemotherapy trials, two advanced non–small-cell lung cancer and two advanced hormone-refractory prostate cancer, with or without baseline CSF. CSF was defined as a rating of two or greater on the Functional Assessment of Cancer Therapy fatigue question or a European Organization for Research and Treatment of Cancer Quality of Life Questionnaire—Core 30 fatigue symptom score of 50% or greater. Survival was compared according to CSF using Kaplan-Meier estimates and Cox regression models. Differences in AE rates by CSF were assessed via chi-squared tests, and QOL changes from baseline to 3 months via linear regression. RESULTS: Of 1,994 participants, 1,907 (median age 69 years, range: 32-91) had complete baseline QOL survey data, with 52% reporting CSF at baseline. For the two hormone-refractory prostate cancer studies, baseline CSF was associated with higher mortality rates, with adjusted hazard ratios of (95% CI, P value) 1.32 (1.13 to 1.55, P < .001) and 1.31 (1.02 to 1.67, P = .03) and with increased incidence of grade 3-5 constitutional (16.5% v 9.4%, P = .002; 13.9% v 6.3%, P = .002) and neurologic (11.7% v 6.1%, P = .006; 9.0% v 3.9%, P = .01) AEs, respectively. Baseline CSF was associated with a higher mortality rate in one non–small-cell lung cancer study: hazard ratio 1.44 and 1.04 to 2.00, P = .03. CONCLUSION: Oncology trial participants with baseline CSF had poorer survival and experienced more AEs than participants without CSF. This indicates fatigue as an important baseline prognostic factor in oncology treatment trials.
A Review of Irritable Bowel Syndrome—Reply
Camilleri, Michael

Mayo Clinic

JAMA | July 13, 2021 | Volume: 326 | Issue: 2 | Pages: 189

10.1001/jama.2021.6758 | PMID 34255010 Get It

Cost Conversations About Anticoagulation Between Patients With Atrial Fibrillation and Their Clinicians
Giblon, Rachel , Kunneman, Marlene, Lee, Alexander I., Hargraves, Ian , Sivly, Angela , Burnett, Bruce , Gorr, Haeshik, Roldan, Victor D. Torres , Spencer-Bonilla, Gabriella, Shah, Nilay D. , Brito, Juan P. , Investigators, Shared Decision Making for Atrial Fibrillation (SDM4AFib) Trial, Haffke, Alexander, Stier, Amy, Thota, Anjali, Simpson, Benjamin , Zeballos‐Palacios, Claudia , Vanmeter, Derek , Behnken, Emma , Ting, Henry H. , Anderson, Joel, Inselman, Jonathan , Muegge, Jule , Fleming, Kirsten, Olive, Marc, Vang, Miamoua, Ferrara, Michael J. , Wambua, Mike , Organick, Paige, Cabalka, Renee, Poplau, Sara , Abullarade, Carol, Keune, Shelly, Smith, Timothy D. , Barksdale, Bryan, Peters, Roma, Price, Memrie, Watson, Connie, Wolfe, Douglas A. , Haynes, Brian, Daniels, Paul R. , Jaeger, Thomas M. , Kamath, Celia C , Branda, Megan E. , Hargraves, Ian G, Sivly, Angela L, Torres Roldan, Victor D , Brito, Juan P , Kamath, Celia , Lee, Alexander I., Bellolio, Fernanda , Jackson, Elizabeth A. , Burnett, Bruce, Noseworthy, Peter A. , Montori, Víctor M. , Investigators, Shared Decision Making for Atrial Fibrillation (SDM4AFib) Trial, LeBlanc, Annie , Hess, Erik P. , Hamilton, James, Fleming, Kirsten, Linzer, Mark , Suzuki, Takeki , Harvey, Lisa Anne , Stephens, Shannon W. , Hickey, Theresa, Guyatt, Gordon , Tomlinson, George , Gersh, Bernard J. , McBane, Robert D.

Mayo Clinic

JAMA Network Open | July 13, 2021 | Volume: 4 | Issue: 7 | Pages: e2116009

10.1001/jamanetworkopen.2021.16009 | PMID 34255051 Get It

Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk
Li, Yafang , Xiao, Xiangjun , Byun, Jinyoung , Cheng, Chao , Bossé, Yohan , McKay, James , Lam, Stephen , Tardón, Adonina , Chen, Chu , Landi, Maria Teresa , Wichmann, Erich, Goodman, Gary, Field, John K. , Shete, Sanjay , Melander, Olle , Andrew, Angeline S. , Grankvist, Kjell , Johansson, Mikael , Caporaso, Neil E. , Aldrich, Melinda C. , Schwartz, Ann G. , Gorlov, Ivan P. , Purrington, Kristen S. , Yang, Ping , Bailey‐Wilson, Joan E. , Liu, Yanhong , Mandal, Diptasri , Gaba, Colette , Brennan, Paul , Cheng, Chao , Wilson, Richard K , Field, John K , Tardón, Adonina , Bossé, Yohan , Grankvist, Kjell , Purrington, Kristen S , Byun, Jinyoung , Li, Jianrong , Albanes, Demetrius , Bojesen, Stig E. , Johansson, Mattias , Risch, Angela , Bickeböller, Heike , Christiani, David C. , Rennert, Gad , Arnold, Susanne M. , Marchand, Loı̈c Le , Brunnström, Hans , Liu, Geoffrey , Hung, Rayjean J. , Kiemeney, Lambertus A. , Shen, Hongbing , Sun, Ryan , Zienolddiny, Shanbeh , Teare, M. Dawn , Hong, Yun‐Chul , Davies, Michael P.A. , Lazarus, Philip J. , Schabath, Matthew B. , Han, Younghun , Pinney, Susan M. , Willey, James C. , Amos, Christopher I.

Mayo Clinic

No container title available | July 13, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-647012/v1 Get It

Abstract There is growing evidence showing that sex disparity in lung cancer risk cannot be fully explained by sex differences in smoking behavior, implying existence of genetic and molecular basis for sex disparity in lung cancer development. However, the information about sex dimorphism in lung cancer risk is quite limited despite the great success in lung cancer association studies. By adopting a stringent two-stage analysis strategy, we performed a genome-wide gene-sex interaction analysis using genotype from a lung cancer cohort including ~ 47,000 individuals with European ancestry. Three low-frequency variants (minor allele frequency < 0.05), rs17662871 (OR=0.71, p=4.29x10-8); rs79942605 (OR=2.17, p=2.81x10-8); and rs208908 (OR=0.70, p=4.54x10-8), were identified with different risk effect of lung cancer between men and women. Further eQTL and functional annotation analysis suggested rs208908 affect lung cancer risk through differential regulation of CXADR (Coxsackie Virus And Adenovirus Receptor) gene expression in lung tissues between men and women. Our study is one of the first studies to provide novel insights about the genetic and molecular basis for sex disparity in lung cancer development.
Response to "Reflection on the Evaluation of Radiologists' Performance during Off-Hours Shifts"
Pizzitola, Victor J. , Johnson, C. Daniel , Patel, Maitray D , Johnson, C Daniel , Patel, Maitray D.

Mayo Clinic

Radiology | July 13, 2021 | Volume: 300 | Issue: 3 | Pages: E350-E350

10.1148/radiol.2021210258 | PMID 34254856 Get It

Intramural Ova of Enterobius vermicularis in the Appendix—An Egg-Topic Location!
Mendos, Angelina, Mathison, Blaine A. , Pritt, Bobbi S. , Lamps, Laura W. , Pai, Sanjay A , Pritt, Bobbi S , Mathison, Blaine A

Mayo Clinic

International Journal of Surgical Pathology | July 13, 2021 | Volume: 30 | Issue: 2 | Pages: 214-216

10.1177/10668969211032455 | PMID 34255564 Get It

We report an unusual case of appendicitis in a 9-year-old girl in whom the wall of the appendix contained necrotizing granulomas, as well as eggs of Enterobius vermicularis. Although luminal E vermicularis adult parasites are commonly identified in the appendix and luminal eggs are occasionally seen, intramural worms and eggs are rare. We are unaware of earlier reports of ectopic intramural eggs in the appendix. It is important to and make a correct diagnosis, as both, the patient, as well as the family should be treated for enterobiasis.
HER-2 Neu gene: A valuable therapeutic target in metastatic mucoepidermoid carcinoma
Mohammed, Turab , Mangeshkar, Shaunak , Desai, Aakash , Hegde, Upendra P. , Desai, Aakash P

Mayo Clinic

Journal of Oncology Pharmacy Practice | July 13, 2021 | Volume: 27 | Issue: 7 | Pages: 1806-1809

10.1177/10781552211032722 | PMID 34255585 Get It

Introduction Salivary gland neoplasms (SGNs) respond poorly to the traditional chemotherapy agents limiting the availability of systemic treatment options in the metastatic setting. The recent identification of actionable molecular targets in SGNs has led to the evaluation of targeted therapies in non-approved advanced SGNs. Case Report We present the case of an elderly male with HER-2 Neu overexpressing metastatic mucoepidermoid carcinoma (MEC) who demonstrated a prompt and sustained disease response to targeted therapies directed against HER-2 Neu with long survival interrupted by hepatoxicity to Trastuzumab emtansine (TDM-1) treatment. Management and Outcome: The patient was started on Trastuzumab and Pertuzumab on a clinical trial and resulted in an objective improvement sustained over 3 years. Following the disease progression, TDM-1 was started with a response until the patient developed severe hepatotoxicity as an adverse effect of TDM-1 therapy resulting in its discontinuation. Close follow-up post-treatment-discontinuation demonstrated continued clinical improvement until 6 months, when the patient developed brain metastasis. He passed away a few months later in hospice care. Discussion The metastatic MEC in our patient overexpressed HER-2 Neu. Owing to Trastuzumab and Pertuzumab response, Trastuzumab emtansine (TDM-1) was initiated on a compassionate basis which further extended the survival but had to be terminated owing to adverse effects. Given the paucity of data on targeted therapies in the treatment of metastatic SGNs and the safety, tolerability, and efficacy of TDM-1 therapy among the elderly, further studies are warranted to answer these important questions and to identify eligible patients for this novel treatment option.
Trendelenburg position for internal jugular vein catheterization: A systematic review and meta-analysis
García-Leal, Mariana , Verdines-Perez, Adrian Manuel, León-Gutiérrez, Humberto de , Fernandez‐Rodarte, Bernardo Alfonso , Álvarez‐Villalobos, Neri Alejandro , Martínez‐Garza, Javier Humberto , Quiroga‐Garza, Alejandro , de Leon-Gutierrez, Humberto, Alvarez-Villalobos, Neri Alejandro, Quiroga-Garza, Alejandro , Álvarez-Villalobos, Neri A , Guzman-Lopez, Santos , Elizondo-Omana, Rodrigo Enrique

Mayo Clinic

The Journal of Vascular Access | July 13, 2021 | Volume: 24 | Issue: 2 | Pages: 338-347

10.1177/11297298211031339 | PMID 34254560 Get It

To determine the effect of Trendelenburg position on the diameter or cross-section area of the internal jugular vein (IJV) a systematic review and metanalysis was performed. Studies that evaluated the cross-sectional area (CSA) and anteroposterior (AP) diameter of the right internal jugular vein (RIJV) with ultrasonography in supine and any degree of head-down tilt (Trendelenburg position) were analyzed. A total of 22 articles (613 study subjects) were included. A >5° Trendelenburg position statistically increases RIJV CSA and AP diameter. Further inclination from 10° does not statistically benefit IJV size. This position should be recommended for CVC placement, when patient conditions allow it, and US-guided cannulation is not available.